IBSA Group and Inception Fertility want to make the embryo transfer process a little simpler for patients—and we need your help to make that progress.

IBSA, a multinational pharmaceutical company, recognizes current methods of administering progesterone before and after a frozen embryo transfer (FET) can be painful, messy, and stressful for patients. The company has partnered with Inception Fertility and its family of brands, including the Prelude Network™, to complete a research study evaluating the effectiveness of administering progesterone by subcutaneous injection, an injection under the skin, rather than painful daily injections into a muscle or messy vaginal creams/gels or inserts.

A hormone that plays an important role in early pregnancy, progesterone is considered the standard of care for support during the luteal phase of a woman’s menstrual cycle, when the lining of the uterus thickens to support a potential pregnancy. During a FET cycle, progesterone is usually administered for 4 days prior to the transfer. If the cycle results in a pregnancy, expectant mothers will continue to administer progesterone up to the 10-12th week of pregnancy. This study seeks to find an easier way to administer this vital hormone, helping to make the embryo transfer process more patient-friendly and less painful.